Current Report Filing (8-k)
March 28 2019 - 5:12PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
March 28, 2019
Date of Report
MARKER
THERAPEUTICS, INC.
(Exact name of registrant as specified in
its charter)
Delaware
|
001-37939
|
45-4497941
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
3200 Southwest Freeway
Suite 2240
Houston, Texas
|
|
77027
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(713) 400-6400
Registrant’s telephone number, including
area code
N/A
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company
¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
¨
Item 8.01
Other Events.
On
March 28, 2019, Marker Therapeutics, Inc. (“Marker” or the “Company”) issued a press release providing
business and clinical updates and an overview of highlights for 2019.
A
copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
In accordance with the requirements of the
Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this
28
th
day of March, 2019.
|
MARKER THERAPEUTICS, INC.
(Registrant)
|
|
|
|
|
|
BY:
|
/s/ Michael Loiacono
|
|
|
Michael Loiacono
Chief Accounting Officer
|
Marker Therapeutics (NASDAQ:MRKR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Marker Therapeutics (NASDAQ:MRKR)
Historical Stock Chart
From Sep 2023 to Sep 2024